Keywords: Vectura, GlaxoSmithKline, Dry powder formulations, Licensing, Janssen, Depomed, Acuform, Johnson & Johnson

Vectura boosted by deal with GSK worth over $30 million upfront plus royalties; J&J unit buys rights to Acuform technology

Article | 06 August 2010

Print This

The UK’s Vectura Group, which earlier this year suffered a significant blow when Swiss drug major Novartis’ generics unit ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in